Display options
Share it on

Clin Ophthalmol. 2015 Aug 18;9:1477-81. doi: 10.2147/OPTH.S36650. eCollection 2015.

Noninfectious uveitis: strategies to optimize treatment compliance and adherence.

Clinical ophthalmology (Auckland, N.Z.)

Rosa Dolz-Marco, Roberto Gallego-Pinazo, Manuel Díaz-Llopis, Emmett T Cunningham, J Fernando Arévalo

Affiliations

  1. Unit of Macula, Department of Ophthalmology, University and Polytechnic Hospital La Fe, Spain.
  2. Faculty of Medicine, University of Valencia, Spain.
  3. Department of Ophthalmology, California Pacific Medical Center, San Francisco, CA, USA ; Department of Ophthalmology, Stanford University School of Medicine, Stanford, CA, USA ; The Francis I Proctor Foundation, University of California San Francisco Medical Center, San Francisco, CA, USA ; West Coast Retina Medical Group, San Francisco, CA, USA.
  4. Vitreoretina Division, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia ; Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

PMID: 26316689 PMCID: PMC4547652 DOI: 10.2147/OPTH.S36650

Abstract

Noninfectious uveitis includes a heterogenous group of sight-threatening ocular and systemic disorders. Significant progress has been made in the treatment of noninfectious uveitis in recent years, particularly with regard to the effective use of corticosteroids and non-corticosteroid immunosuppressive drugs, including biologic agents. All of these therapeutic approaches are limited, however, by any given patient's ability to comply with and adhere to their prescribed treatment. In fact, compliance and adherence are among the most important patient-related determinants of treatment success. We discuss strategies to optimize compliance and adherence.

Keywords: adherence; compliance; immunosuppressive treatment; intraocular inflammation; noninfectious uveitis; therapeutic failure

References

  1. Eye (Lond). 2010 Aug;24(8):1409-10 - PubMed
  2. Prog Retin Eye Res. 2011 Nov;30(6):452-70 - PubMed
  3. Ther Clin Risk Manag. 2008 Feb;4(1):269-86 - PubMed
  4. Inflamm Allergy Drug Targets. 2013 Feb;12(1):38-45 - PubMed
  5. Br J Clin Pharmacol. 2007 Apr;63(4):383-4 - PubMed
  6. Ocul Immunol Inflamm. 2009 Nov-Dec;17(6):423-30 - PubMed
  7. Clin Exp Ophthalmol. 2004 Dec;32(6):563-8 - PubMed
  8. Surv Ophthalmol. 2008 Mar-Apr;53(2):139-49 - PubMed
  9. Eur J Ophthalmol. 2013 Sep-Oct;23(5):705-17 - PubMed
  10. Curr Opin Ophthalmol. 1995 Jun;6(3):57-61 - PubMed
  11. Br J Ophthalmol. 1996 Sep;80(9):844-8 - PubMed
  12. Transplant Proc. 2003 Nov;35(7):2609-11 - PubMed
  13. J Adv Nurs. 1994 Feb;19(2):233-8 - PubMed
  14. J Psychosom Res. 1999 Dec;47(6):491-5 - PubMed
  15. Patient Prefer Adherence. 2013 Jul 10;7:675-82 - PubMed
  16. N Engl J Med. 2005 Aug 4;353(5):487-97 - PubMed
  17. Med Hypothesis Discov Innov Ophthalmol. 2013 Winter;2(4):113-20 - PubMed
  18. Eye (Lond). 2012 Jan;26(1):17-28 - PubMed
  19. Reumatol Clin. 2011 Nov-Dec;7(6):385-8 - PubMed
  20. Br J Ophthalmol. 2010 Jul;94(7):813-4 - PubMed
  21. Eye (Lond). 1998;12 ( Pt 4):679-85 - PubMed
  22. MedGenMed. 2005 Mar 16;7(1):4 - PubMed
  23. Int Ophthalmol Clin. 2010 Spring;50(2):1-17 - PubMed
  24. JAMA Ophthalmol. 2013 Jun;131(6):787-9 - PubMed
  25. Ann Allergy. 1991 Nov;67(5):481-6 - PubMed
  26. Transplantation. 1995 Feb 15;59(3):340-7 - PubMed
  27. Indian J Ophthalmol. 2014 Jan;62(1):74-81 - PubMed
  28. Transplant Proc. 1999 Feb-Mar;31(1-2):1326-7 - PubMed
  29. Am J Ophthalmol. 2006 Jan;141(1):218-20 - PubMed
  30. Arch Ophthalmol. 2011 May;129(5):545-53 - PubMed
  31. J Am Pharm Assoc (2003). 2013 Mar-Apr;53(2):172-81 - PubMed
  32. Contemp Clin Trials. 2014 Mar;37(2):234-41 - PubMed
  33. Ophthalmology. 2009 Nov;116(11 Suppl):S43-7 - PubMed
  34. J Transpl Coord. 1999 Jun;9(2):104-8 - PubMed
  35. Hu Li Za Zhi. 2014 Aug;61(4):21-5 - PubMed

Publication Types